IMbrave150: A randomised phase III study of atezolizumab + bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma

Autor:	S. Qin, Andrew X. Zhu, Michel Ducreux, Tae Yong Kim, Masafumi Ikeda, Peter R. Galle, Juan Liu, Derek-Zhen Xu, Wendy Verret, Richard S. Finn, A-L Cheng
Rok vydání:	2018
Předmět:	Sorafenib Oncology medicine.medical_specialty Randomization Bevacizumab business.industry Locally advanced Hematology Atezolizumab Internal medicine medicine Metastatic hepatocellular carcinoma business medicine.drug
Zdroj:	Annals of Oncology. 29:ix66
ISSN:	0923-7534
DOI:	10.1093/annonc/mdy432.060
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::70f47d5fa3cc80a11ea2e6918bcd132c https://doi.org/10.1093/annonc/mdy432.060 Zobrazit plný text záznamu